A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
11/16/2023
Locations: The Memory Clinic, Bennington, Vermont
Conditions: Alzheimer's Disease
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
10/16/2023
Locations: The Memory Clinic, Bennington, Vermont
Conditions: Alzheimer Disease
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
Recruiting
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
10/10/2023
Locations: Memory Clinic Inc, Bennington, Vermont
Conditions: Alzheimer Disease
Cholinergic Health After Menopause (CHAMP)
Recruiting
Women are at increased risk for Alzheimer's disease (AD). Notably at menopause, some women experience a change in cognition. However, not all women experience negative effects of menopause on cognition. The cognitive changes that occur at menopause have not yet been connected to late life risk for pathological aging including AD. Thus, understanding the neurobiological factors related to individual differences in cognition at menopause is critical for understanding normal cognitive aging and for... Read More
Gender:
Female
Ages:
Between 50 years and 70 years
Trial Updated:
05/08/2023
Locations: University of Vermont, Burlington, Vermont
Conditions: Postmenopausal Symptoms, Aging, Alzheimer Disease